The Miami Myeloma MRD Virtual Meeting 2023 take places on 6 April at 9am – 1pm EST/2pm – 6pm BST/3pm -7pm CEST. Hosted by the Sylvester Comprehensive Cancer Center’s Myeloma Research Institute, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation, the workshop will bring together leading experts in multiple myeloma who will discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion.

VJHemOnc is pleased to be the official media partner for the meeting.

Hear more from Meeting Chair
Ola Landgren, Sylvester Comprehensive Cancer Center’s Myeloma Research Institute, USA

Agenda 16.03.2023 (All times in EST)

9:00AM-9:05AM
Introduction

Welcome and Introduction: Ola Landgren, Director of Sylvester Comprehensive Cancer Center’s Myeloma Research Institute

9:05AM-10:00AM
SESSION 1: CURRENT ERA OF MRD TESTING IN MYELOMA

MAIA study: sustained MRD status in non-transplant eligible patients
Nizar Bahlis

DETERMINATION study: upfront vs delayed transplant, by MRD status?
Paul Richardson

CASTOR study: MRD status in relapsed/refractory myeloma
Katja Weisel

Sustained MRD negativity on maintenance therapy
Urvi Shah

9:50AM-10:00AM
LIVE Q&A: Moderated by Dickran Kazandjian

10:00AM-10:15AM
LIVE DISCUSSION: PATIENT PERSPECTIVES ON MRD TESTING IN MYELOMA

A perspective from Yelak Biru – IMF Patient, President & CEO of IMF

Live panel discussion: Moderated by Ola Landgren

10:15AM-11:10AM
SESSION 2: CURRENT AND EMERGING TECHNOLOGIES FOR TRACKING OF MRD IN MYELOMA

Mass-spec using MALDI-TOF, BindingSite Technology
Niels Weinhold

Whole genome sequencing of circulating tumor cells
Jean-Baptiste Alberge

Individualized serum peptides, Sebia Technology
Katie Thoren

V(D)J tracking in bone marrow and peripheral blood, Adaptive Technology
Malin Hultcrantz

10:55AM-11:10AM
LIVE Q&A: Moderated by David Coffey

11:10AM-11:25AM

LIVE DISCUSSION: PERSPECTIVES ON AVAILABLE AND NEW MRD ASSAYS IN MYELOMA

A perspective from George Mulligan, CSO of MMRF

Moderated by Ola Landgren

11:25AM-11:45AM

FIRESIDE LUNCH CHAT WITH THE FDA: MRD IN MYELOMA, TODAY AND TOMORROW

Nicole Gormley, Division Director at the FDA & Ola Landgren

11:45AM-12:40PM

SESSION 3: TREATMENT-DECISIONS BASED ON MRD IN MYELOMA

Update MASTER trial
Luciano Costa

University of Chicago treatment cessation study
Benjamin Derman

MSKCC treatment cessation study
Neha Korde

Role of normalization of bone marrow microenvironment
David Coffey

12:25PM-12:40PM

LIVE Q&A: Moderated by Benjamin Diamond

12:40PM-12:55PM

LIVE DISCUSSION: USING MRD TESTING IN THE REAL-WORLD

A perspective from Jennifer Ahlstrom, MM Patient, Founder of HealthTree Foundation

Moderated by Ola Landgren

12:55PM-1:00PM 
LIVE SUMMARY DISCUSSION

Webinar concluding comments with Jennifer Ahlstrom, George Mulligan, Yelak Biru and
Ola Landgren

1:00PM
Conclusions/Adjourn: Ola Landgren

The Miami Myeloma MRD 2023 Meeting is supported by: